CO7101241A2 - Formulaciones de antibióticos - Google Patents

Formulaciones de antibióticos

Info

Publication number
CO7101241A2
CO7101241A2 CO14158889A CO14158889A CO7101241A2 CO 7101241 A2 CO7101241 A2 CO 7101241A2 CO 14158889 A CO14158889 A CO 14158889A CO 14158889 A CO14158889 A CO 14158889A CO 7101241 A2 CO7101241 A2 CO 7101241A2
Authority
CO
Colombia
Prior art keywords
antibiotic formulations
suspension formulation
antibiotic
formulations
administration
Prior art date
Application number
CO14158889A
Other languages
English (en)
Inventor
Alawi Fadil Al
Karthigeyan Nanjan
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7101241(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CO7101241A2 publication Critical patent/CO7101241A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068—Rumen, e.g. rumen bolus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación en suspensión para su administración a un animal, la formulación en suspensión incluyendo: al menos un antibiótico de cefalosporina o una sal farmacéutciamente similar de la misma; un aceite; y un disolvente de acetato de glicerina.
CO14158889A 2011-12-23 2014-07-22 Formulaciones de antibióticos CO7101241A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ59738911 2011-12-23

Publications (1)

Publication Number Publication Date
CO7101241A2 true CO7101241A2 (es) 2014-10-31

Family

ID=48668892

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14158889A CO7101241A2 (es) 2011-12-23 2014-07-22 Formulaciones de antibióticos

Country Status (15)

Country Link
KR (1) KR20140102319A (es)
CN (1) CN104080456A (es)
AU (1) AU2012359296B2 (es)
BR (1) BR112014014786A2 (es)
CL (1) CL2014001602A1 (es)
CO (1) CO7101241A2 (es)
CR (1) CR20140355A (es)
DO (1) DOP2014000146A (es)
IL (1) IL233299A0 (es)
MX (1) MX2014007735A (es)
MY (1) MY167596A (es)
NI (1) NI201400064A (es)
PE (1) PE20142373A1 (es)
PH (1) PH12014501384A1 (es)
WO (1) WO2013095166A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014014364A1 (en) 2012-07-17 2014-01-23 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
EP2874624B8 (en) 2012-07-17 2019-10-02 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
CA3132159C (en) * 2019-03-06 2023-11-21 Zoetis Services Llc A ready-to-use injectable formulation comprising cefovecin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US7767860B2 (en) * 2007-09-06 2010-08-03 Auspex Pharmaceuticals, Inc Substituted amino alcohols
CN101401787B (zh) * 2008-11-19 2011-05-18 肖希龙 一种头孢噻呋长效注射液及其制备方法
CN101953889B (zh) * 2010-09-07 2013-04-10 西北农林科技大学 一种复方头孢噻呋混悬乳剂注射液及其制备方法

Also Published As

Publication number Publication date
WO2013095166A1 (en) 2013-06-27
PH12014501384A1 (en) 2014-09-22
BR112014014786A2 (pt) 2017-06-13
MY167596A (en) 2018-09-20
KR20140102319A (ko) 2014-08-21
CR20140355A (es) 2014-10-29
AU2012359296B2 (en) 2014-12-11
NI201400064A (es) 2014-11-28
IL233299A0 (en) 2014-08-31
MX2014007735A (es) 2014-08-01
CN104080456A (zh) 2014-10-01
DOP2014000146A (es) 2014-07-31
CL2014001602A1 (es) 2014-10-24
AU2012359296A1 (en) 2013-08-01
PE20142373A1 (es) 2015-02-11

Similar Documents

Publication Publication Date Title
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
EP3016653A4 (en) Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
BR112014002845A2 (pt) “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
BR112014025041B8 (pt) Composição farmacêutica
BR112014026149A2 (pt) método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
CA2904820C (en) Pyridinylpyrazoloquinoline compound
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
CR20140355A (es) Formulaciones de antibióticos
EP2722322B8 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
BR112013019283A2 (pt) composto, fármaco, composição farmacêutica e uso
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
EA201400444A1 (ru) Производные 2-оксопиперидинила
TR200904500A2 (tr) Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
BR112014022687A2 (pt) Uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo
UY34839A (es) Formulaciones de antibiótico